ULUR Stock Overview
ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ULURU Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ULUR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -3.7% |
| 1Y | n/a | 11.6% | 20.5% |
Return vs Industry: Insufficient data to determine how ULUR performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ULUR performed against the US Market.
Price Volatility
| ULUR volatility | |
|---|---|
| ULUR Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ULUR has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ULUR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Vaidehi Shah | www.uluruinc.info |
ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain.
ULURU Inc. Fundamentals Summary
| ULUR fundamental statistics | |
|---|---|
| Market cap | US$29.00 |
| Earnings (TTM) | -US$2.20m |
| Revenue (TTM) | US$568.74k |
0.0x
P/S Ratio0.0x
P/E RatioIs ULUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ULUR income statement (TTM) | |
|---|---|
| Revenue | US$568.74k |
| Cost of Revenue | US$152.22k |
| Gross Profit | US$416.53k |
| Other Expenses | US$2.62m |
| Earnings | -US$2.20m |
Last Reported Earnings
Sep 30, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ULUR perform over the long term?
See historical performance and comparison